In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to VolitionRX (VNRX – Research Report),

In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to VolitionRX (VNRX – Research Report),
In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on VolitionRX (VNRX – Research Report), with
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to VolitionRX (VNRX – Research Report),
Yesterday it was reported that a Director at VolitionRX (VNRX – Research Report), Guy Archibald Innes, exercised options to buy
Yesterday, the President & CEO of VolitionRX (VNRX – Research Report), Cameron John Reynolds, bought shares of VNRX for $11K.
In a report released yesterday, Mark Breidenbach from Oppenheimer assigned a Buy rating to VolitionRX (VNRX – Research Report), with
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to VolitionRX (VNRX – Research Report),